Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Reversal of COPD-associated weight loss using the anabolic agent oxandrolone.

Yeh SS, DeGuzman B, Kramer T; M012 Study Group.

Chest. 2002 Aug;122(2):421-8.

PMID:
12171812
3.

Resistance exercise and supraphysiologic androgen therapy in eugonadal men with HIV-related weight loss: a randomized controlled trial.

Strawford A, Barbieri T, Van Loan M, Parks E, Catlin D, Barton N, Neese R, Christiansen M, King J, Hellerstein MK.

JAMA. 1999 Apr 14;281(14):1282-90.

PMID:
10208143
4.

Body cell mass repletion and improved quality of life in HIV-infected individuals receiving oxandrolone.

Earthman CP, Reid PM, Harper IT, Ravussin E, Howell WH.

JPEN J Parenter Enteral Nutr. 2002 Nov-Dec;26(6):357-65.

PMID:
12405647
6.

Oxandrolone in the treatment of HIV-associated weight loss in men: a randomized, double-blind, placebo-controlled study.

Grunfeld C, Kotler DP, Dobs A, Glesby M, Bhasin S.

J Acquir Immune Defic Syndr. 2006 Mar;41(3):304-14.

PMID:
16540931
7.

Closure of the "non-healing wound" corresponds with correction of weight loss using the anabolic agent oxandrolone.

Demling R, De Santi L.

Ostomy Wound Manage. 1998 Oct;44(10):58-62, 64, 66 passim.

PMID:
9866597
8.
9.

Oxandrolone treatment in adults with severe thermal injury.

Miller JT, Btaiche IF.

Pharmacotherapy. 2009 Feb;29(2):213-26. doi: 10.1592/phco.29.2.213. Review.

PMID:
19170590
11.

Treatment with an anabolic agent is associated with improvement in respiratory function in persons with tetraplegia: a pilot study.

Spungen AM, Grimm DR, Strakhan M, Pizzolato PM, Bauman WA.

Mt Sinai J Med. 1999 May;66(3):201-5.

PMID:
10377553
12.

Evaluation of the effects of oxandrolone on malnourished HIV-positive pediatric patients.

Fox-Wheeler S, Heller L, Salata CM, Kaufman F, Loro ML, Gilsanz V, Haight M, Umman GC, Barton N, Church JA.

Pediatrics. 1999 Dec;104(6):e73.

PMID:
10586007
13.

The effects of oxandrolone and exercise on muscle mass and function in children with severe burns.

Przkora R, Herndon DN, Suman OE.

Pediatrics. 2007 Jan;119(1):e109-16. Epub 2006 Nov 27.

14.

Should androgenic anabolic steroids be considered in the treatment regime of selected chronic obstructive pulmonary disease patients?

Velema MS, Kwa BH, de Ronde W.

Curr Opin Pulm Med. 2012 Mar;18(2):118-24. doi: 10.1097/MCP.0b013e32834e9001. Review.

PMID:
22189453
15.

The effect of oxandrolone on the endocrinologic, inflammatory, and hypermetabolic responses during the acute phase postburn.

Jeschke MG, Finnerty CC, Suman OE, Kulp G, Mlcak RP, Herndon DN.

Ann Surg. 2007 Sep;246(3):351-60; discussion 360-2.

16.

Comparing megestrol acetate therapy with oxandrolone therapy for HIV-related weight loss: similar results in 2 months.

Mwamburi DM, Gerrior J, Wilson IB, Chang H, Scully E, Saboori S, Miller L, Forfia J, Albrecht M, Wanke CA.

Clin Infect Dis. 2004 Mar 15;38(6):895-902. Epub 2004 Mar 1.

17.

The influence of 6 months of oral anabolic steroids on body mass and respiratory muscles in undernourished COPD patients.

Ferreira IM, Verreschi IT, Nery LE, Goldstein RS, Zamel N, Brooks D, Jardim JR.

Chest. 1998 Jul;114(1):19-28.

PMID:
9674442
18.
19.

Oxandrolone use in Crohn's disease.

Kravetz JD, Lee C, Dieterich DT.

Am J Gastroenterol. 1997 Dec;92(12):2330-1. No abstract available.

PMID:
9399787
20.

Five-year outcomes after oxandrolone administration in severely burned children: a randomized clinical trial of safety and efficacy.

Porro LJ, Herndon DN, Rodriguez NA, Jennings K, Klein GL, Mlcak RP, Meyer WJ, Lee JO, Suman OE, Finnerty CC.

J Am Coll Surg. 2012 Apr;214(4):489-502; discussion 502-4. doi: 10.1016/j.jamcollsurg.2011.12.038.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk